← Leaderboards
Matteo Porotto
Weill Medical Coll Of Cornell Univ
$18,361,086
Attributed
$20,249,439
Total exposure
16
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,249,439 · 16
By mechanism
R01$15,203,248 · 6
R56$2,837,804 · 5
R21$2,208,387 · 5
Top collaborators
- Rik L De Swart4 shared
- Erica Ollmann Saphire1 shared
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralPeptidesInfectionVirus DiseasesPreventMediatingCellsVirusCell MembraneIn VivoMembrane FusionMembraneIn VitroProteinsVaccinesAntiviral AgentsGlycoproteinsLeadDesignBiodistributionToxic EffectReceptorLipidsDisease Outbreaks
Grant awards (42)
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2$710,512
R01 · FY2025 · AI · contact PI
Design of fusion inhibitors to block measles host-to-host infection$701,927
R01 · FY2025 · AI · contact PI
Thermostable measles fusion glycoprotein as a new vaccine strategy$883,864
R56 · FY2024 · AI · contact PI
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2$711,960
R01 · FY2024 · AI · contact PI
Design of fusion inhibitors to block measles host-to-host infection$703,309
R01 · FY2024 · AI · contact PI
Design of fusion inhibitors to block measles host-to-host infection$736,876
R01 · FY2023 · AI · contact PI
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2$714,110
R01 · FY2023 · AI · contact PI
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2$716,622
R01 · FY2022 · AI · contact PI
Development of therapeutic fusion inhibitor peptides for Measles encephalitis$354,375
R01 · FY2022 · NS · contact PI
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2$750,151
R01 · FY2021 · AI · contact PI
Design of fusion inhibitors to block measles host-to-host infection$561,162
R56 · FY2021 · AI · contact PI
Development of therapeutic fusion inhibitor peptides for Measles encephalitis$354,375
R01 · FY2021 · NS · contact PI
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agents$659,766
R01 · FY2020 · AI · contact PI
Development of therapeutic fusion inhibitor peptides for Measles encephalitis$354,375
R01 · FY2020 · NS · contact PI
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agents$661,567
R01 · FY2019 · AI · contact PI
Self-assembling nanoparticles for intranasal delivery of influenza fusion inhibitors$643,028
R01 · FY2019 · AI · contact PI
Small molecules to block measles spreading in the central nervous system$492,576
R56 · FY2019 · AI · contact PI
Mechanisms of measles virus CNS adaptation$373,600
R01 · FY2019 · NS · contact PI
Development of therapeutic fusion inhibitor peptides for Measles encephalitis$354,375
R01 · FY2019 · NS · contact PI
Self-assembling nanoparticles for intranasal delivery of influenza fusion inhibitors$644,883
R01 · FY2018 · AI · contact PI
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agents$610,838
R01 · FY2018 · AI · contact PI
Mechanisms of measles virus CNS adaptation$373,600
R01 · FY2018 · NS · contact PI
Development of therapeutic fusion inhibitor peptides for Measles encephalitis$354,375
R01 · FY2018 · NS · contact PI
Self-assembling nanoparticles for intranasal delivery of influenza fusion inhibitors$684,836
R01 · FY2017 · AI · contact PI
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agents$606,731
R01 · FY2017 · AI · contact PI
Mechanisms of measles virus CNS adaptation$373,600
R01 · FY2017 · NS · contact PI
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agents$704,548
R01 · FY2016 · AI · contact PI
Self-assembling nanoparticles for intranasal delivery of influenza fusion inhibitors$547,102
R01 · FY2016 · AI · contact PI
Mechanisms of measles virus CNS adaptation$373,600
R01 · FY2016 · NS · contact PI
Mechanisms of measles virus CNS adaptation$428,207
R01 · FY2015 · NS · contact PI
Self-assembling nanoparticles for intranasal delivery of influenza fusion inhibitors$342,459
R56 · FY2015 · AI · contact PI
Measles infection blockage by intranasal delivery of F targeting peptides$557,743
R56 · FY2014 · AI · contact PI
Development of antivirals for newly emerging pathogens Ebola and Marburg.$227,010
R21 · FY2013 · AI · contact PI
Active and arrested paramyxovirus fusion machinery visualized by cryo-electron to$220,978
R21 · FY2013 · AI · contact PI
Development of antivirals for newly emerging pathogens Ebola and Marburg.$218,900
R21 · FY2012 · AI · contact PI
Active and arrested paramyxovirus fusion machinery visualized by cryo-electron to$213,779
R21 · FY2012 · AI · contact PI
Bioengineering protocells for a new class of viral vaccines$211,250
R21 · FY2012 · EB · contact PI
Novel brain-penetrant fusion inhibitors for control of CNS infection.$191,724
R21 · FY2012 · NS · contact PI
Development of therapeutic fusion inhibitor peptides for Measles encephalitis$189,861
R21 · FY2012 · NS · contact PI
Bioengineering protocells for a new class of viral vaccines$253,500
R21 · FY2011 · EB · contact PI
Novel brain-penetrant fusion inhibitors for control of CNS infection.$251,245
R21 · FY2011 · NS · contact PI
Development of therapeutic fusion inhibitor peptides for Measles encephalitis$230,140
R21 · FY2011 · NS · contact PI